Page last updated: 2024-10-16

quinacrine and Creutzfeldt-Jakob Syndrome

quinacrine has been researched along with Creutzfeldt-Jakob Syndrome in 26 studies

Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.

Creutzfeldt-Jakob Syndrome: A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))

Research Excerpts

ExcerptRelevanceReference
"Quinacrine was administrated to a CJD patient who received a cadaveric dura mater graft and developed CJD 23 years later."5.32[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation]. ( Hirata, K; Kobayashi, Y; Tanaka, H; Yamada, T, 2003)
"The quinacrine-treated group, however, declined less on 2 of 3 functional scales, the modified Rankin and Clinical Dementia Rating, than the placebo group during the first 2 months."2.78Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. ( Cheng, HQ; Dearmond, SJ; Devereux, G; Duncan, JL; Finley, R; Forner, SA; Garcia, P; Geschwind, MD; Haman, A; Johnson, DY; Kuo, AL; Miller, BL; Neuhaus, JM; Possin, KL; Prusiner, SB; Raudabaugh, BJ; Thai, JN; Torres-Chae, CC; Wong, KS, 2013)
"Quinacrine at 300 mg/day was given enterally for 3 months."2.71Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. ( Furukawa, H; Kataoka, Y; Kusuhara, T; Nakajima, M; Takahashi, M; Yamada, T; Yamauchi, A, 2004)
"Treatment with quinacrine and chlorpromazine for acquired CJD was ineffective in our patient."1.33Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. ( Bermejo, J; Contreras, MA; Guerrero, MC; Lunar, A; Martínez Pérez, M; Martínez-Lage, JF; Rábano, A, 2005)
"Quinacrine was administrated to a CJD patient who received a cadaveric dura mater graft and developed CJD 23 years later."1.32[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation]. ( Hirata, K; Kobayashi, Y; Tanaka, H; Yamada, T, 2003)
"Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD)."1.32Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. ( Alpérovitch, A; Belorgey, C; Boher, E; Brandel, JP; Delasnerie-Lauprêtre, N; Faucheux, BA; Haïk, S; Hauw, JJ; Laplanche, JL; Salomon, D; Sazdovitch, V; Soubrié, C, 2004)
" When compared clinical effects by quinacrine and the combination therapy, improvement of clinical findings was observed at the same level without any adverse effects."1.32Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. ( Eguchi, K; Katamine, S; Kataoka, Y; Nishida, N; Niwa, M; Satoh, K; Shirabe, S; Yamauchi, A, 2004)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's23 (88.46)29.6817
2010's2 (7.69)24.3611
2020's1 (3.85)2.80

Authors

AuthorsStudies
Miranda, LHL1
Oliveira, AFPH1
Carvalho, DM1
Souza, GMF1
Magalhães, JGM1
Júnior, JAC1
Lima, PTMBQ1
Júnior, RMA1
Filho, SPL1
Melo, HMA1
Geschwind, MD1
Kuo, AL1
Wong, KS1
Haman, A1
Devereux, G1
Raudabaugh, BJ1
Johnson, DY1
Torres-Chae, CC1
Finley, R1
Garcia, P1
Thai, JN1
Cheng, HQ1
Neuhaus, JM1
Forner, SA1
Duncan, JL1
Possin, KL1
Dearmond, SJ1
Prusiner, SB1
Miller, BL1
Teruya, K1
Doh-Ura, K1
Furukawa, H2
Takahashi, M2
Nakajima, M2
Yamada, T3
Collins, SJ1
Lewis, V1
Brazier, M1
Hill, AF1
Fletcher, A1
Masters, CL1
Follette, P1
Scoazec, JY1
Krolak-Salmon, P1
Casez, O1
Besson, G1
Thobois, S1
Kopp, N1
Perret-Liaudet, A1
Streichenberger, N1
Kobayashi, Y1
Hirata, K1
Tanaka, H1
Giles, J1
Tuma, RS1
Kusuhara, T1
Yamauchi, A2
Kataoka, Y2
Nanri, Y1
Kuroda, Y1
Butcher, J1
Brown, H1
Arruda, WO1
Bordignon, KC1
Milano, JB1
Ramina, R1
Pauri, F1
Amabile, G1
Fattapposta, F1
Pierallini, A1
Bianco, F1
Haïk, S1
Brandel, JP1
Salomon, D1
Sazdovitch, V1
Delasnerie-Lauprêtre, N1
Laplanche, JL1
Faucheux, BA1
Soubrié, C1
Boher, E1
Belorgey, C1
Hauw, JJ1
Alpérovitch, A1
Satoh, K1
Shirabe, S1
Eguchi, K1
Niwa, M1
Nishida, N1
Katamine, S1
Bertrand, A1
Martinez-Almoyna, L1
De Broucker, T1
Benito-León, J1
Martínez-Lage, JF1
Rábano, A1
Bermejo, J1
Martínez Pérez, M1
Guerrero, MC1
Contreras, MA1
Lunar, A1
Love, R1
Josefson, D1
Braunholtz, D1
Harris, J1
Cooper, E1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092]Phase 269 participants (Actual)Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Change in Phonemic Fluency (Words Beginning With Letter D)"

"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months

Interventionnumber of words generated (Mean)
Placebo-2.4
Quinacrine-2.2

ADAS-Cog Change After 2 Months Among Survivors

ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo13.0
Quinacrine12.6

Barthel Score Change After 2 Months

An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months

Interventionunits on a scale (Mean)
Placebo-23.2
Quinacrine-13.2

Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months

Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo3.2
Quinacrine0.3

Change in Mini-Mental State Examination (MMSE) After 2 Months

The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2

Interventionunits on a scale (Mean)
Placebo-6.9
Quinacrine-3.9

Change in Rankin Score After 2 Months

"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo0.8
Quinacrine0.3

Change in Semantic Verbal Fluency (Naming Animals)

Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionnumber of words generated (Mean)
Placebo-3.2
Quinacrine-2.2

Primary Survival

Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2

Interventionparticipants (Number)
Placebo19
Quinacrine13

Reviews

4 reviews available for quinacrine and Creutzfeldt-Jakob Syndrome

ArticleYear
Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?
    Arquivos de neuro-psiquiatria, 2022, Volume: 80, Issue:8

    Topics: Aminopyridines; Creutzfeldt-Jakob Syndrome; Doxycycline; Humans; Pentosan Sulfuric Polyester; Prion

2022
Insights from Therapeutic Studies for PrP Prion Disease.
    Cold Spring Harbor perspectives in medicine, 2017, Mar-01, Volume: 7, Issue:3

    Topics: Aminopyridines; Animals; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Doxycycline; Drug Disco

2017
[Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:8

    Topics: Animals; Antimalarials; Blood-Brain Barrier; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; H

2002
[Creutzfeldt-Jakob disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl

    Topics: Antimalarials; Antipsychotic Agents; Biomarkers; Brain; Chlorpromazine; Creutzfeldt-Jakob Syndrome;

2004

Trials

2 trials available for quinacrine and Creutzfeldt-Jakob Syndrome

ArticleYear
Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.
    Neurology, 2013, Dec-03, Volume: 81, Issue:23

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Creutzfeldt-Jakob Syndrome; Double-Blind Metho

2013
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease.
    Dementia and geriatric cognitive disorders, 2004, Volume: 17, Issue:3

    Topics: Antimalarials; Creutzfeldt-Jakob Syndrome; Electroencephalography; Eye Movements; Female; Head Movem

2004

Other Studies

20 other studies available for quinacrine and Creutzfeldt-Jakob Syndrome

ArticleYear
Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.
    Annals of neurology, 2002, Volume: 52, Issue:4

    Topics: Animals; Creutzfeldt-Jakob Syndrome; Disease Models, Animal; Enzyme Inhibitors; Female; Mice; Mice,

2002
New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels.
    Science (New York, N.Y.), 2003, Jan-10, Volume: 299, Issue:5604

    Topics: Animals; Brain; Brain Chemistry; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Drug Evaluati

2003
Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease.
    Annals of neurology, 2003, Volume: 53, Issue:4

    Topics: Antimalarials; Chemical and Drug Induced Liver Injury; Creutzfeldt-Jakob Syndrome; Humans; Quinacrin

2003
[Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft--an EEG evaluation].
    Rinsho shinkeigaku = Clinical neurology, 2003, Volume: 43, Issue:7

    Topics: Adult; Cadaver; Creutzfeldt-Jakob Syndrome; Dura Mater; Electroencephalography; Female; Humans; Orga

2003
Rapid drug trial offers hope to CJD patients.
    Nature, 2003, Dec-04, Volume: 426, Issue:6966

    Topics: Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Humans; Quinacrine; Time Factors; Treatment Fa

2003
Drug designers seek a structural solution.
    Drug discovery today, 2003, Nov-15, Volume: 8, Issue:22

    Topics: Animals; Cattle; Creutzfeldt-Jakob Syndrome; Drug Design; Quinacrine; Structure-Activity Relationshi

2003
CJD researchers close to agreeing plans for first clinical trial. Arguments have marred discussions about protocol design, prompting allegations of "academic jealousy".
    Lancet (London, England), 2004, Apr-10, Volume: 363, Issue:9416

    Topics: Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Humans; Quinacrine; Research Design

2004
Fast-track CJD trial: two years late, but not derailed.
    The Lancet. Neurology, 2004, Volume: 3, Issue:5

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Humans; Quinacrine

2004
[Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings].
    Arquivos de neuro-psiquiatria, 2004, Volume: 62, Issue:2A

    Topics: Antimalarials; Antipsychotic Agents; Blotting, Western; Creutzfeldt-Jakob Syndrome; Diffusion Magnet

2004
Sporadic Creutzfeldt-Jakob disease without dementia at onset: clinical features, laboratory tests and sequential diffusion MRI (in an autopsy-proven case).
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2004, Volume: 25, Issue:4

    Topics: 14-3-3 Proteins; Brain; Creutzfeldt-Jakob Syndrome; Dementia; Diagnosis, Differential; Diffusion Mag

2004
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
    Neurology, 2004, Dec-28, Volume: 63, Issue:12

    Topics: Brain; Creutzfeldt-Jakob Syndrome; Disease Progression; Drug Evaluation; Humans; Quinacrine; Surviva

2004
Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease.
    Cellular and molecular neurobiology, 2004, Volume: 24, Issue:6

    Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Creutzfeldt-Jakob Syndrome; Female; H

2004
[Hereditary Creutzfeldt-Jakob disease caused by a mutation at codon 200].
    Revue neurologique, 2005, Volume: 161, Issue:3

    Topics: 14-3-3 Proteins; Brain; Codon; Creutzfeldt-Jakob Syndrome; Electroencephalography; Enzyme Inhibitors

2005
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
    Neurology, 2005, May-24, Volume: 64, Issue:10

    Topics: Adult; Brain; Chlorpromazine; Creutzfeldt-Jakob Syndrome; DNA Mutational Analysis; Dopamine Antagoni

2005
Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine.
    Surgical neurology, 2005, Volume: 64, Issue:6

    Topics: Adult; Arnold-Chiari Malformation; Cadaver; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Dopamine Ant

2005
Old drugs to treat new variant Creutzfeldt-Jakob disease.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Animals; Antimalarials; Antipsychotic Agents; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Drug Thera

2001
Drugs for malaria and psychosis may offer hope to people with CJD.
    BMJ (Clinical research ed.), 2001, Aug-25, Volume: 323, Issue:7310

    Topics: Adult; Antimalarials; Antipsychotic Agents; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Female; Huma

2001
Quinacrine in possible or probable CJD: if you had suspected CJD would you be indifferent between placebo and quinacrine?
    BMJ (Clinical research ed.), 2002, Jan-26, Volume: 324, Issue:7331

    Topics: Control Groups; Creutzfeldt-Jakob Syndrome; Enzyme Inhibitors; Ethics, Clinical; Humans; Quinacrine;

2002
Quinacrine in possible or probable CJD: it is blinded investigators, not patients, who must be in equipoise over treatment.
    BMJ (Clinical research ed.), 2002, Jan-26, Volume: 324, Issue:7331

    Topics: Creutzfeldt-Jakob Syndrome; Enzyme Inhibitors; Ethics, Clinical; Humans; Quinacrine; Randomized Cont

2002
Compassion comes before science.
    New scientist (1971), 2001, Aug-18, Volume: 171, Issue:2304

    Topics: Clinical Trials as Topic; Creutzfeldt-Jakob Syndrome; Empathy; Humans; Quinacrine; Research Design;

2001